The global artificial organs market size was valued at USD 30.86 billion in 2025 and is projected to grow from USD 33.38 billion in 2026 to USD 62.46 billion by 2034, registering a CAGR of 8.15% during the forecast period from 2026 to 2034. North America dominated the artificial organs market with a market share of 39.5% in 2025.
Artificial organs are evolving from temporary mechanical support devices to biologically integrated solutions that replicate real tissue functionality. Personalized designs using 3D bioprinting and computational modeling allow organs to fit individual patient anatomy and reduce immune rejection. Advances in biomaterials and regenerative medicine have enabled lab-grown kidneys to survive for up to six months in preclinical models and artificial hearts to support continuous blood flow of over five liters per minute in animal studies.
Download a Free Sample To learn more about this report,
Advancement of Biohybrid Artificial Organs Combining Living Cells and Devices
The limitations of fully mechanical replacement systems are encouraging researchers to combine living cells or engineered tissues with synthetic components in biohybrid organ technologies. This transition is creating systems that can use biological functions alongside mechanical support, potentially improving physiological interaction and functional performance. For example, researchers working on an implantable bioartificial kidney have developed a hybrid concept that combines silicon nanopore membranes with living kidney cells to filter blood and concentrate waste into urine.
Development of Patient-Specific Artificial Organs Using Digital Modeling
The anatomical differences between patients are encouraging the use of medical imaging and digital modeling to design artificial organs and engineered tissue structures for individual requirements. This transition is improving the ability to reproduce patient-specific anatomy and create customized constructs for research, surgical planning, and future regenerative applications. For example, a 2025 study used CT angiography data from stroke patients to digitally reproduce patient-specific carotid artery geometries and create personalized artery-on-a-chip models through digital light 3D printing.
Donor Organ Shortage and Transplant Waiting Times Drive Market
The limited supply of suitable donor organs creates a need for artificial organs and organ-support technologies that can provide alternatives to conventional transplantation. UNOS reports that more than 49,000 organ transplants were performed in the U.S. in 2025, while its current information notes that there are not enough organs for everyone who needs a transplant. For example, ventricular assist devices can support patients with advanced heart failure when a donor heart is not immediately available. This supply gap supports the use of artificial organ technologies and encourages manufacturers to provide reliable organ-replacement and support systems.
The time required to obtain a suitable donor organ creates requirements for technologies that can maintain organ function while patients await transplantation. UNOS states that most transplant candidates wait for some period because there are not enough organs available for all patients in need. For example, the FDA has approved ventricular assist systems for use as a bridge to cardiac transplantation in patients with advanced heart failure. This clinical requirement supports adoption of artificial organ and organ-support technologies that help eligible patients remain supported while awaiting transplantation.
Patient-Specific Requirements and Infrastructure Limitations Restrain Market Expansion
Complex patient-specific requirements arise from differences in patient anatomy, organ size, disease conditions, and physiological needs, which can require customized designs and treatment planning. FDA notes that patient-specific medical devices can be created from individual patient imaging data and may require designs matched to specific anatomical features. These customization requirements can increase production and clinical complexity, limiting standardized manufacturing and slowing the wider adoption of artificial organs.
Limited infrastructure for advanced implantation and follow-up can restrict access to specialized hospitals, surgical facilities, medical technologies, and multidisciplinary healthcare teams. WHO identifies reliable infrastructure, appropriate medical technologies, and specialized health workers as essential components for effective hospital services, while noting persistent disparities in workforce availability. These infrastructure gaps can limit the availability of artificial organ procedures and long-term monitoring, slowing market penetration and growth.
Advanced Biomaterials and Strategic Transplant Center Partnerships Offers Growth Opportunities
Biomaterial companies, artificial-organ manufacturers, medical-device developers, and research institutions can develop biocompatible materials that improve durability, flexibility, and tissue interaction. These materials create revenue through specialized components and higher-value artificial organ systems, with companies such as Gore and Covestro developing biomaterials and polymers for medical-device applications.
Artificial-organ developers, transplant centers, hospitals, and research institutions can collaborate on clinical testing, device validation, implantation protocols, and specialized patient programs. These partnerships create revenue through device supply agreements, clinical services, and technology development programs, with companies such as SynCardia and Abiomed working with hospitals on advanced circulatory support technologies.
Reimbursement Uncertainty and Specialized Supply Constraints Hinders Growth
The high costs associated with artificial organs, implantation, monitoring, and replacement can create uncertainty about healthcare reimbursement. Limited or inconsistent coverage can reduce patient access and make hospitals more cautious about adopting expensive technologies. This uncertainty can weaken demand and make revenue forecasting difficult for manufacturers.
Manufacturers rely on specialized polymers, coatings, membranes, sensors, microelectronics, and precision components that may have limited supplier bases. Supply interruptions can delay production and increase procurement costs. These constraints can make it difficult for companies to scale manufacturing and maintain reliable product availability.
The artificial heart segment accounted for a share of 29.4% in 2025, owing to the increasing prevalence of advanced heart failure, rising demand for cardiac replacement technologies, and growing adoption of artificial heart systems for patients with severe cardiac conditions. the increasing need for advanced cardiac support and improvements in artificial heart technology further strengthen the segment’s dominant position in the artificial organs market.
The bio-artificial liver segment is expected to grow at a CAGR of 11.2% during the forecast period, driven by increasing prevalence of liver disorders, rising demand for advanced liver support technologies, and growing research in bioengineered organ systems. the prosthetic heart valves segment supports cardiac valve replacement procedures, while the ventricular assist devices segment provides mechanical circulatory support for patients with severe heart failure. the cardiac pacemakers & ICDs segment contributes through cardiac rhythm management, while the artificial kidney segment supports renal replacement therapy and dialysis applications. the artificial pancreas segment benefits from growing demand for automated diabetes management, while the artificial lungs/ECMO segment supports respiratory and cardiopulmonary care. the cochlear & auditory brain-stem implants segment contributes to hearing restoration and auditory rehabilitation, while the other organ types segment includes additional artificial and bioengineered organ technologies.
Request Customizationto receive a tailored report.
The mechanical segment accounted for a share of 42.8% in 2025 due to the widespread use of mechanical artificial organs and devices for supporting or replacing organ functions, along with their established clinical applications and proven reliability. the increasing demand for durable and effective organ support technologies further strengthens the segment’s dominant position in the artificial organs market.
The 3D-bioprinted constructs segment is expected to grow at a CAGR of 12.5% during the forecast period, fueled by increasing investment in regenerative medicine, advances in tissue engineering and bioprinting technologies, and growing research into personalized artificial organs. the electronic/bionics segment supports organ function through advanced electronic and sensor-based systems, while the wearable/externally worn segment contributes through portable technologies that provide continuous or assisted organ support.
The hospitals segment accounted for a share of 64.2% in 2025, supported by the widespread use of artificial organs and related technologies for complex surgeries, organ replacement, critical care, and long-term patient management. the availability of advanced medical infrastructure, specialized healthcare professionals, and comprehensive treatment facilities further strengthens the segment’s dominant position in the artificial organs market.
The ambulatory surgical centers segment is expected to grow at a CAGR of 9.4% during the forecast period, propelled by the increasing shift toward minimally invasive procedures, rising demand for outpatient surgical care, and growing adoption of advanced organ-related medical technologies. the other end users segment includes specialized clinics, research institutions, rehabilitation centers, and other healthcare settings that support the use of artificial organs and related technologies.
Speak to an Analystto discuss market opportunities.
The North America artificial organs market accounted for the largest regional share of 39.5% in 2025, driven by advanced healthcare infrastructure, increasing adoption of artificial organ technologies, and strong investments in medical research and regenerative medicine. The U.S. artificial organs market is supported by continued regulatory advancement of artificial organ technologies, particularly artificial hearts and ventricular assist systems. The FDA approved a 2025 post-approval study protocol for the SynCardia temporary Total Artificial Heart and issued further approvals for the system in 2025–2026, while NIH research continues to advance artificial organs and regenerative medicine, including engineered heart and lung models.
The Canada artificial organs market is supported by an established medical-device and implant infrastructure. Innovation, Science and Economic Development Canada estimates Canada's medical devices market at US$10.06 billion in 2024, with orthopaedic and prosthetic products accounting for 11.6% of the market, while Health Canada regulates implants and prosthetics that replace or support missing body parts and recognizes standards specifically covering cardiovascular implants and artificial organs.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific artificial organs market is expected to grow at a CAGR of 10.6%, showcasing the fastest-growing regional market, driven by rising demand for organ replacement therapies, improving healthcare infrastructure, and increasing investments in advanced medical technologies. In Japan, the Ministry of Health, Labour and Welfare (MHLW) is continuing to strengthen its organ-transplantation system through the FY2026 Organ Transplant Implementation Support Program, scheduled to begin on October 1, 2026. MHLW is also maintaining a dedicated regenerative-medicine framework, including 2026 measures covering the safe provision of regenerative medicine and the manufacture of specified cell-processed products, supporting the broader clinical infrastructure surrounding organ replacement and regenerative therapies. In China, the National Medical Insurance Administration reported in March 2026 that China had established medical-service pricing items for biological 3D printing of tissues, blood vessels, and organs, with the pricing framework intended to facilitate the transition of biological 3D printing toward clinical application in areas such as tissue repair and organ reconstruction.
In South Korea, the Ministry of Health and Welfare approved the Second Basic Plan for Advanced Regenerative Medicine and Advanced Biopharmaceuticals (2026–2030) in July 2026, establishing a five-year framework to support advanced regenerative medicine, expand treatment infrastructure, and strengthen research and treatment using advanced technologies. The South Korean government also identifies xenotransplantation research as an R&D area, including genetically modified pigs, preclinical research, and clinical-research protocols. In India, the Department of Biotechnology reported that Sree Chitra Tirunal Institute for Medical Sciences and Technology developed Chitra-GelMA-UVS Bioink, an indigenous bioink for 3D bioprinting of tissues associated with organs including the liver, kidney, pancreas, skin, brain, and heart, with the technology transferred to an Indian company for commercialization, supporting advances in biofabrication and tissue engineering relevant to artificial-organ technologies.
The Europe artificial organs market accounted for a regional share of 28.2% in 2025, supported by strong biomedical research capabilities, growing adoption of innovative organ replacement technologies, and increasing demand for advanced therapeutic solutions. In the U.K. artificial organs market, the government announced £22 million in August 2026 for projects aimed at replacing animal testing, including a £20 million centre to grow miniature organs from human tissue. The centre will develop human-tissue-based organ models for more accurate testing, supporting advances in tissue engineering and artificial-organ-related technologies.
In the Germany artificial organs market, the Bundestag approved a reform of living-organ donation in March 2026, enabling cross-over living kidney donation between two or more donor-recipient pairs and establishing a national cross-over kidney-donation program. The reform also expands access to living donation and strengthens donor protection, supporting the broader organ-replacement and transplantation ecosystem. Meanwhile, the France artificial organs market is supported by continued demand for organ-replacement solutions, with France recording 6,148 organ transplants in 2025, the highest number ever recorded in the country and 95 more than in 2024. At the beginning of 2026, 23,294 patients were waiting for an organ transplant, including 11,642 on the active waiting list, highlighting the ongoing need for organ-replacement and transplantation solutions.
The Middle East and Africa artificial organs market is expected to grow at a CAGR of 7.6%, supported by improving healthcare infrastructure, increasing access to advanced medical treatments, and growing investments in healthcare technology. The UAE artificial organs market is expected to benefit from the country’s expanding organ transplantation infrastructure and advanced medical capabilities. In August 2026, the Department of Health – Abu Dhabi reported that more than 2,150 patients had benefited from organ transplants through the national Hayat programme since its launch in 2017, including complex procedures that were among the first of their kind in the UAE and region. The emirate’s advanced transplantation capabilities and continued development of specialized healthcare infrastructure are expected to support future adoption of artificial and bioengineered organ technologies.
The Africa artificial organs market is expected to benefit from efforts to strengthen transplantation systems, medical-product regulation, and access to advanced health technologies. In June 2026, WHO released its draft Global Strategy on Donation and Transplantation, which aims to address disparities in access to transplantation and strengthen quality, safety, and oversight of human cell, tissue, and organ transplantation. WHO’s African Region also maintains a dedicated programme covering organs, tissues, and transplants while supporting countries in strengthening regulatory capacity and health technologies.
The artificial organs market is moderately fragmented, with medical device manufacturers, biotechnology companies, regenerative medicine companies, implantable device developers, tissue engineering companies, and specialized artificial organ technology providers competing across organ replacement, transplantation, and advanced healthcare applications. Established players compete primarily on device performance, biocompatibility, clinical efficacy, safety, durability, technological innovation, regulatory compliance, research and development, manufacturing capabilities, product reliability, and clinical support, with leading players such as Medtronic, Abbott, Boston Scientific Corp., Johnson and Johnson Services Inc., and Fresenius Medical Care AG estimated to account for approximately 55% of the global market based on their product portfolios, technological capabilities, clinical expertise, geographic presence, and competitive positioning.
Emerging and regional players within the artificial organs market ecosystem compete through cost-effective solutions, compact and innovative designs, advanced biomaterials, customized devices, minimally invasive technologies, flexible manufacturing, specialized applications, and rapid product development to address specific patient requirements and strengthen their market presence. These players also focus on developing advanced biomaterials, improving device miniaturization, and introducing specialized organ replacement technologies to differentiate their offerings and expand their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Radiosurgery Market Size, Share, Growth, Analysis, Report, 2034
Interventional Cardiology Devices Market Size, Share, Growth, 2034
Smart Inhalers Market Size, Share, Growth, Analysis, Report, 2034
Irradiation Apparatus Market Size, Share, Growth, Analysis, 2034
ECG Patch and Holter Monitor Market Size, Share, Growth, 2034
Dermatology Excimer Laser Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com